Lapatinib in breast cancer: clinical experiences and future perspectives

被引：17

作者：

Giampaglia, M. ^{[1
]}

Chiuri, V. E.

Tinelli, A. ^{[2
]}

De Laurentiis, M. ^{[3
,4
]}

Silvestris, N. ^{[5
]}

Lorusso, V.

机构：

[1] Osped Vito Fazzi, Med Oncol Unit, UO Oncologia Med, I-73100 Lecce, Italy

[2] Osped Vito Fazzi, Dept Obstet & Gynaecol, I-73100 Lecce, Italy

[3] Natl Canc Intitute Fdn Pascale, Dept Breast Oncol, Naples, Italy

[4] Univ Naples Federico II, Dept Endocrinol & Mol & Clin Oncol, Naples, Italy

[5] Canc Inst Giovanni Paolo II, Med & Expt Oncol Unit, Bari, Italy

来源：

CANCER TREATMENT REVIEWS | 2010年 / 36卷

关键词：

Breast cancer; EGFR; HER2; Lapatinib; Trastuzumab; Anthracycline; Taxane; Chemotherapy; Tyrosine-kinase inhibitor; DUAL KINASE INHIBITOR; PHASE-II TRIAL; BRAIN METASTASES; GW572016; LAPATINIB; BIOMARKER PROFILES; TYROSINE KINASES; PLUS TRASTUZUMAB; DOSE-ESCALATION; OPEN-LABEL; COMBINATION;

D O I：

10.1016/S0305-7372(10)70024-4

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Lapatinib, an orally available dual inhibitor targeting the tyrosine-kinase domain of both epidermal growth factor receptor-1 and 2, has been introduced for the treatment of advanced/metastatic HER2+ breast cancer in combination with capacitabine after chemotherapy regimens containing anthracycline, taxanes and trastuzumab. Moreover, lapatinib is under investigation in combination with anthracycline and taxanes in neoadjuvant and adjuvant settings. Another potential field of investigation for this drug is related to its ability to restore hormonal sensitivity of HER2-, hormone-receptor positive breast cancer cells. This paper reviews the current use of lapatinib in breast cancer and its future perspectives. (C) 2010 Elsevier Ltd. All rights reserved.

引用

页码：S72 / S79

页数：8

共 50 条

[31] Artificial intelligence in breast cancer: application and future perspectives
Yan, Shuixin
Li, Jiadi
Wu, Weizhu
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (17) : 16179 - 16190
[32] Hereditary breast and ovarian cancer: review and future perspectives
Lux, MP
Fasching, PA
Beckmann, MW
JOURNAL OF MOLECULAR MEDICINE-JMM, 2006, 84 (01): : 16 - 28
[33] Hereditary breast and ovarian cancer: review and future perspectives
Michael P. Lux
Peter A. Fasching
Matthias W. Beckmann
Journal of Molecular Medicine, 2006, 84 : 16 - 28
[34] Systemic treatment of HER2+metastatic breast cancer: Clinical conundrums and future perspectives
De Boer, Richard
Beith, Jane
Chirgwin, Jacquie
Chua, Sue
Colosimo, Maree
Francis, Prudence
Green, Michael
Pittman, Ken
White, Michelle
Wilcken, Nicholas
Zdenkowski, Nicholas
Bell, Richard
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2014, 10 : 15 - 25
[35] The clinical development of vaccines for HER2+ breast cancer: Current landscape and future perspectives
Costa, R. L. B.
Soliman, H.
Czerniecki, B. J.
CANCER TREATMENT REVIEWS, 2017, 61 : 107 - 115
[36] Experiences of an Exercise Program: Perspectives from Breast Cancer Survivors
Anisimowicz, Yvonne
Rudy, Lauren
Hamilton, Ryan
McGowan, Erin
Saunders, Travis
Keats, Melanie
Grandy, Scott
Soucy, Courtni Ruth-Anne
Bouchard, Danielle
QUALITATIVE REPORT, 2021, 26 (08) : 2479 - 2501
[37] Breast Cancer Screening: Implications and Clinical Perspectives
Guraya, Salman Yousuf
JOURNAL OF TAIBAH UNIVERSITY MEDICAL SCIENCES, 2008, 3 (02): : 67 - 82
[38] Patient and public involvement in clinical guidelines: international experiences and future perspectives
Boivin, Antoine
Currie, Kay
Fervers, Beatrice
Gracia, Javier
James, Marian
Marshall, Catherine
Sakala, Carol
Sanger, Sylvia
Strid, Judi
Thomas, Victoria
van der Weijden, Trudy
Grol, Richard
Burgers, Jako
QUALITY & SAFETY IN HEALTH CARE, 2010, 19 (05):
[39] Future Roles of Lapatinib in ErbB2-Positive Breast Cancer: Adjuvant and Neoadjuvant Trials
Costa, Serban-Dan
Jackisch, Christian
Thomssen, Christoph
BREAST CARE, 2010, 5 : 22 - 24
[40] The Role of Lapatinib in the Preoperative Therapy of Breast Cancer
Hirsh, Rebecca L.
DeMichele, Angela
CURRENT ONCOLOGY REPORTS, 2012, 14 (01) : 44 - 47

← 1 2 3 4 5 →